IQVIA Holdings Inc. research snapshot
IQV AI stock analysis currently reads IQVIA Holdings as a scaled life sciences data, analytics, commercial services, and clinical research platform with improving 2026 momentum, strong free cash flow, and a large R&D Solutions backlog. At the July 8, 2026 data cutoff, IQV traded near $208.23 with a verified market capitalization of about $34.75 billion. The main offset is leverage: IQVIA carried about $15.83 billion of debt and $13.89 billion of net debt at March 31, 2026. This page uses scenarios, technical levels, and source-backed facts. It is informational research, not investment advice.
Current price
$208.23
Market cap
$34.75 billion
AI score
73 / 100
Rating
Scaled healthcare intelligence and clinical research platform with leverage and execution risk
Trend status
Bullish short-term momentum, above both the 50-day and 200-day moving averages
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | IQVIA sells clinical research services, healthcare data, analytics, technology, and commercial services to life sciences and healthcare clients. The model benefits from scale, contracts, data depth, and recurring client relationships. | High |
| Moat | The moat comes from proprietary healthcare data, global trial execution capacity, regulatory know-how, client switching costs, analytics workflow integration, and a contracted R&DS backlog of $34.2 billion at March 31, 2026. | High |
| Management | Ari Bousbib remains chairman and CEO, bringing continuity since the 2016 Quintiles and IMS Health merger. Capital allocation has favored buybacks, acquisitions, and platform scale, but leverage discipline is central. | Medium-high |
| Financial trend | FY2025 revenue was $16.310 billion and net income attributable to IQVIA was $1.360 billion. Q1 2026 revenue rose 8.4% to $4.151 billion and adjusted diluted EPS was $2.90. | High |
| Valuation | At $208.23, IQV traded near 25.9x TTM EPS, 5.6x book value, 16.4x free cash flow per share, 2.1x sales, and 16.3x EV/EBITDA. The stock is not cheap on leverage-adjusted metrics. | High |
| Technical trend | The stock was above its 50-day moving average near $177.56 and 200-day moving average near $195.61, while RSI near 73.16 showed strong but potentially stretched momentum. | Medium |
| Risk level | Key risks are debt load, refinancing cost, trial cancellation cycles, biotech funding pressure, pharma outsourcing changes, data privacy regulation, acquisition integration, and multiple compression. | Medium-high |
| AI confidence | High for descriptive research and audited calculations. Lower for exact return outcomes because small changes in bookings, interest expense, or PE multiple can move the equity materially. | High data confidence |
| Investment certainty | Medium certainty. The business has scale and cash flow, but the balance sheet and cyclicality of life sciences spending reduce the margin of safety. | Medium |
IQV AI stock forecast
The IQV AI stock forecast uses scenario math around the $208.23 quote and the midpoint of management 2026 adjusted diluted EPS guidance near $12.80. The audited three-year framework produced a bearish area near $177, a base area near $282, and a bullish area near $385 before any future buyback effect. The range is wide because IQVIA combines a sticky client platform with meaningful financial leverage.
$360 to $400
More likely if adjusted EPS compounds near 11% annually, R&DS backlog converts on schedule, Commercial Solutions sustains high-single-digit growth, acquisitions add clean revenue, free cash flow funds debt reduction and buybacks, and the market values IQV near 22x earnings.
$260 to $300
More likely if adjusted EPS compounds near 7% annually, 2026 guidance is met, R&DS bookings stay above 1.0x book-to-bill, Commercial Solutions remains steady, interest expense is manageable, and IQV trades around 18x earnings.
$165 to $185
More likely if trial cancellations rise, biotech funding weakens, backlog conversion slows, debt refinancing costs stay high, privacy or data access rules tighten, and the market compresses IQV toward 13x earnings.
IQV AI technical analysis
IQV AI technical analysis is constructive but stretched as of the July 8, 2026 cutoff. Price was above both the 50-day and 200-day moving averages, while RSI was above 70. Technical levels should be refreshed with live chart data before trading.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $208.23 | July 7, 2026 close used for market cap and valuation math at the July 8 data cutoff. |
| Near support | $195 to $200 | The 200-day moving average near $195.61 and the $200 round-number area form the first support band if momentum cools. |
| Deeper support | $177 to $180 | The 50-day moving average near $177.56 is the deeper trend reference after the recent rally. |
| Near resistance | $220 to $226 | This band combines round-number supply with the current third-party average analyst target near $226.47, so it is a practical upside reference rather than a promise. |
| 50-day moving average | About $177.56 | Price was well above this intermediate trend gauge, supporting a positive short-term trend. |
| 200-day moving average | About $195.61 | Price was above this long-term gauge, which supports a repaired broader trend unless it fails on volume. |
| Momentum | RSI about 73.16 | Momentum was strong but above the typical 70 threshold, so new entries need disciplined sizing and invalidation rules. |
| Volume | About 1.60 million average daily shares | Breakouts above resistance should be judged against recent average volume because low-volume moves can fade. |
| Volatility | Beta about 1.20 | IQV tends to move more than the market, especially around earnings, guidance, interest-rate moves, and healthcare spending updates. |
| Invalidation | Close below $195, then $177 | A close below the 200-day moving average would weaken the repaired trend. A break below the 50-day area would signal a deeper failed setup. |
IQV AI trading strategy
The IQV AI trading strategy is a rules-based research framework for a leveraged healthcare intelligence and clinical research platform. It is not personal advice and should be paired with live quotes, filings, position sizing, and risk controls.
Watch for IQV to hold above the 200-day moving average near $196 and build above $220 with volume confirmation, stable 2026 guidance, and no deterioration in R&DS bookings or backlog conversion.
A close below about $195 should invalidate the short-term trend setup, especially if it follows weak earnings, lower bookings, or higher leverage commentary.
If IQV pulls back toward the $177 to $195 support zone without a new demand, debt, or regulatory shock, compare the price with 2026 adjusted EPS guidance, free cash flow, net leverage, and the three-scenario valuation range.
Do not average down without a defined loss limit because leveraged service companies can derate quickly when growth or interest-cost assumptions worsen.
Track R&DS backlog, book-to-bill, cancellations, Commercial Solutions growth, adjusted EBITDA, free cash flow conversion, net leverage, share repurchases, debt refinancing, data privacy regulation, and large pharma budget signals.
Reduce confidence if EPS growth depends mostly on buybacks or multiple expansion while organic revenue, bookings, and debt reduction weaken.
Investment research summary
IQVIA helps pharmaceutical, biotech, medical device, and healthcare clients run trials, analyze healthcare data, commercialize therapies, and make evidence-based decisions. Customers pay because outsourcing trials, data infrastructure, analytics, and commercial execution can be faster and more scalable than building every capability internally.
The moat is built from global trial scale, healthcare data breadth, analytics tools, regulatory experience, client relationships, and workflow integration. It weakens if sponsors pull work in-house, lower-cost CROs win share, privacy rules restrict data usage, or AI tools reduce the value of legacy analytics products.
The thesis fails if R&DS bookings fall below healthy replacement rates, cancellations rise, biotech funding weakens, Commercial Solutions loses pricing power, debt refinancing absorbs free cash flow, or regulators materially restrict data usage.
Ari Bousbib has led IQVIA since the Quintiles and IMS Health merger, giving the company strategic continuity. The key capital allocation question is whether buybacks and acquisitions create value while net leverage remains elevated.
Drug development complexity, real-world evidence, specialty therapies, AI-enabled trial design, and commercial data needs support long-term demand for IQVIA services. The counterweight is that client spending can pause when biotech funding tightens or large pharma reprioritizes pipelines.
IQV is priced as a quality compounder with improving momentum, not as a distressed leveraged service company. Margin of safety depends on sustained free cash flow, guidance execution, backlog conversion, and gradual net debt reduction.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| IQV price | $208.23 close on July 7, 2026 | StockAnalysis market data snapshot | July 8, 2026 |
| Market capitalization | $34.75 billion, verified as $208.23 x 166.90 million shares with 0.01% variance | financial_rigor.py market cap verification | July 8, 2026 |
| Shares outstanding | 166.90 million shares | IQVIA Q1 2026 Form 10-Q and StockAnalysis statistics | July 8, 2026 |
| FY2025 revenue | $16.310 billion, cross-validated against IQVIA FY2025 release, StockAnalysis, and Macrotrends with 0.00% variance | IQVIA FY2025 release and StockAnalysis financials | July 8, 2026 |
| FY2025 net income attributable to IQVIA | $1.360 billion, cross-validated against IQVIA FY2025 release and StockAnalysis with 0.00% variance | IQVIA FY2025 release and StockAnalysis financials | July 8, 2026 |
| Q1 2026 revenue and EPS | $4.151 billion revenue, $274 million GAAP net income attributable to IQVIA, $1.61 GAAP diluted EPS, and $2.90 adjusted diluted EPS | IQVIA Q1 2026 release | July 8, 2026 |
| Cash, debt, and net debt | $1.947 billion cash, $15.833 billion debt, and $13.886 billion net debt at March 31, 2026 | IQVIA Q1 2026 release and 2026 Q1 Form 10-Q | July 8, 2026 |
| R&DS contracted backlog | $34.2 billion at March 31, 2026, with about $8.9 billion expected to convert to revenue in the next twelve months | IQVIA Q1 2026 release | July 8, 2026 |
| 2026 guidance | $17.150 billion to $17.350 billion revenue, $3.975 billion to $4.025 billion adjusted EBITDA, and $12.65 to $12.95 adjusted diluted EPS | IQVIA Q1 2026 release | July 8, 2026 |
| Valuation ratios | 25.9x TTM PE, 5.6x PB, 16.4x P/FCF, 2.1x PS, and 16.3x EV/EBITDA based on StockAnalysis and financial_rigor.py | StockAnalysis statistics and financial_rigor.py valuation verification | July 8, 2026 |
| Technical snapshot | 50-day moving average $177.56, 200-day moving average $195.61, RSI 73.16, beta 1.20, and 20-day average volume about 1.60 million shares | StockAnalysis statistics | July 8, 2026 |
| CEO continuity | Ari Bousbib is chairman and CEO and has held the role since the 2016 Quintiles and IMS Health merger | IQVIA board biography | July 8, 2026 |
| Insider ownership | StockAnalysis reported insiders owned about 0.97% of IQV shares, while institutions owned about 98.44% | StockAnalysis statistics | July 8, 2026 |
This IQV AI stock analysis page is an informational tool only and is not investment advice, financial advice, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available public data as of July 8, 2026 and may be wrong. Always verify live market data, company filings, and your own risk constraints before making investment decisions.
